When a Hemolytic Transfusion Reaction Falsely Raises a MELD Score
Blood Bank results don't exist in a vacuum.
Sometimes something that looks like a transfusion reaction affects far more than the patient's hemoglobin. It can alter renal function, coagulation studies, chemistry results, clinical decision-making—and, in a liver transplant candidate, even the laboratory values used to determine transplant priority.
A fascinating case published in Transfusion in 2023 demonstrated exactly that.
An evolving anti-Jkᵃ caused an acute hemolytic transfusion reaction in a patient with end-stage liver disease. The resulting hemolysis caused a dramatic increase in bilirubin, which in turn made the patient's liver disease appear substantially worse according to the MELD score.
The patient's liver hadn't suddenly deteriorated to the degree suggested by the score.
His transfused red cells were being destroyed.
And that distinction mattered enormously.
What Is the MELD Score?
The Model for End-Stage Liver Disease, or MELD, is used to estimate short-term mortality risk and help determine medical urgency for liver transplantation.
The scoring system has changed over time.
At the time this case occurred, liver allocation in the United States used an earlier version of MELD. Since July 13, 2023, OPTN has used an updated calculation commonly referred to as MELD 3.0.
Current MELD calculation incorporates:
serum bilirubin
serum creatinine
INR
serum sodium
serum albumin
age at listing
sex for adult candidates
Higher scores generally indicate greater short-term mortality risk and therefore greater medical urgency for transplantation.
That system works because those laboratory values ordinarily reflect important consequences of advanced liver disease.
But what happens when something other than worsening liver disease suddenly changes them?
That's where transfusion medicine enters the picture.
Hemolysis Can Distort the Picture
Hemolysis produces bilirubin.
When red blood cells are destroyed, hemoglobin is broken down, heme is metabolized, and unconjugated bilirubin increases.
So if a liver transplant candidate suddenly undergoes substantial intravascular hemolysis, total bilirubin can increase dramatically even if the underlying hepatic function hasn't deteriorated by the same magnitude.
Acute hemolytic transfusion reactions can also produce:
falling hemoglobin and hematocrit
hemoglobinemia
hemoglobinuria
increased LDH
decreased haptoglobin
hyperkalemia
acute kidney injury
hypotension
disseminated intravascular coagulation in severe reactions
Kidney injury can increase creatinine, while severe systemic coagulation activation may also affect coagulation testing.
So in theory, a serious hemolytic transfusion reaction can disturb more than one variable incorporated into a MELD calculation.
But in the 2023 case, the standout problem was bilirubin.
The Case: An Evolving Anti-Jkᵃ
The patient had end-stage liver disease with hepatorenal syndrome and was already listed for liver transplantation.
Before transfusion, antibody testing demonstrated nonspecific reactivity by solid-phase testing.
There wasn't yet enough evidence to definitively identify a specific alloantibody.
Then the patient received Jkᵃ-positive red blood cells.
The previously weak immune response evolved into a detectable anti-Jkᵃ, producing an acute hemolytic transfusion reaction.
And if you've worked in Blood Bank for more than about five minutes, the fact that Kidd was involved probably isn't shocking.
Kidd antibodies are notorious for being difficult.
They can become weak or even undetectable over time and then mount a strong response following re-exposure to the corresponding antigen. They also have the ability to activate complement and can cause clinically significant acute or delayed hemolytic transfusion reactions.
In this patient, what initially looked like nonspecific reactivity turned out to be the beginning of something much more clinically important.
Then the Bilirubin Exploded
Before the hemolytic reaction, the patient's total bilirubin was approximately:
4.7 mg/dL
Following the reaction, it increased to:
17.1 mg/dL
That's not a subtle change.
The patient's MELD score, which had already been high because of his underlying end-stage liver disease, rose from approximately 34 to greater than 40 during the acute hemolytic episode.
A score in that range communicates an extremely high degree of medical urgency.
Except a significant part of the apparent worsening wasn't coming from sudden progression of the patient's liver disease.
It was coming from the destruction of transfused RBCs.
A MELD Score Measures Numbers—Not Their Cause
That's the really interesting part of the case.
MELD is an extremely useful prognostic model, but the equation doesn't know why the bilirubin is elevated.
It sees bilirubin.
It doesn't see:
“Bilirubin is currently elevated because a bunch of Jkᵃ-positive donor RBCs are being destroyed.”
Likewise, a mathematical model can't inherently distinguish renal dysfunction caused by progressive hepatorenal disease from acute renal injury caused by another process.
The laboratory values are real.
The hemolysis is real.
The patient's condition may genuinely be worse because an acute hemolytic transfusion reaction is itself dangerous.
But the resulting MELD score may temporarily overestimate the severity of the underlying hepatic disease that the score is intended to represent.
That becomes important when the number is being used to help allocate an extraordinarily scarce resource.
The Transplant Consequences
A very high MELD score can substantially change a patient's priority for a deceased-donor liver.
In this case, the temporary increase in MELD increased the patient's apparent short-term mortality risk and transplant urgency. The elevated score also had practical consequences for the transfusion service, which had to prepare for the possibility that transplantation could occur while the patient now had a clinically significant anti-Jkᵃ.
That means the same transfusion reaction created two separate problems for the Blood Bank.
First:
The transfusion itself caused hemolysis that altered the patient's transplant-related laboratory values.
Then:
The newly identified anti-Jkᵃ complicated the procurement of compatible blood for the potential liver transplant.
And liver transplants are not exactly procedures where you want to discover at the last minute that compatible RBC inventory is going to be difficult.
What Happened When the Hemolysis Resolved?
This is what helped demonstrate the problem.
As the acute hemolytic episode resolved and the incompatible Jkᵃ-positive donor red cells were cleared from circulation, bilirubin began to fall.
The patient's MELD score fell with it.
The apparent mortality risk moved back toward the patient's pre-reaction baseline.
The liver hadn't magically recovered overnight.
A transient nonhepatic contributor to one of the MELD variables had disappeared.
That's a very important distinction.
“Nonspecific Reactivity” Doesn't Always Mean Nothing
There's another Blood Bank lesson buried in this case.
The initial testing showed nonspecific reactivity rather than an identifiable anti-Jkᵃ.
It's tempting to think of nonspecific reactions as annoying background noise:
"Nothing identifies. Autocontrol is negative. Probably nothing."
Sometimes that really is all it is.
But occasionally you may be looking at an antibody that is still developing.
The authors specifically highlighted this issue because the anti-Jkᵃ initially presented only as nonspecific solid-phase reactivity before becoming clearly identifiable.
That doesn't mean every nonspecific reaction should cause the Blood Bank to start issuing every antigen-negative combination imaginable.
That would be impossible.
But unexplained reactivity deserves to be interpreted in context.
A patient who:
has been repeatedly transfused
has a history of alloantibodies
is likely to require substantial future transfusion
is awaiting major surgery
or is being evaluated for transplantation
may deserve a different level of concern than somebody with an isolated weak nonspecific reaction who is unlikely to receive blood again.
Kidd Being Kidd
Anti-Jkᵃ is particularly appropriate for a case like this because Kidd antibodies have earned their reputation.
A previously stimulated Kidd antibody may fall below the detection threshold of routine testing.
The patient is transfused with antigen-positive RBCs.
The immune system encounters the antigen again.
Antibody production increases.
And suddenly the Blood Bank gets a call because the patient's hemoglobin is falling and their urine looks like Coca-Cola.
The antibody that appeared absent wasn't necessarily gone.
It was simply below detectable levels.
That's why historical clinically significant antibodies matter even when the current antibody screen is negative.
If a patient has previously demonstrated anti-Jkᵃ, they should continue to receive appropriately Jkᵃ-negative RBCs according to transfusion-service policy even if the antibody later becomes undetectable.
Acute Hemolysis Doesn't Necessarily Mean ABO
When most people hear acute hemolytic transfusion reaction, their first thought is an ABO-incompatible transfusion.
And for good reason.
ABO incompatibility is the classic cause of severe acute intravascular hemolysis.
But non-ABO antibodies can also cause acute hemolysis.
Kidd antibodies are especially capable of complement activation and can produce substantial intravascular destruction of transfused RBCs.
So an apparently compatible ABO transfusion doesn't end the investigation when the clinical and laboratory findings indicate hemolysis.
What Would This Mean Under MELD 3.0?
The exact scoring system used in the 2023 report has since changed.
Today's OPTN MELD 3.0 incorporates additional variables, including sodium and albumin, and uses updated coefficients and interactions designed to improve prediction of waitlist mortality.
But the underlying lesson from this case still applies.
Bilirubin remains an important component of MELD 3.0.
So substantial hemolysis can still increase a patient's calculated score.
If the hemolytic reaction also produces acute kidney injury, creatinine may increase as well.
The precise numerical effect would differ under the current formula, but MELD 3.0 still cannot inherently determine whether an abnormal laboratory value arose from progressive hepatic disease, transfusion-associated hemolysis, sepsis, renal injury, anticoagulant therapy, or another acute process.
Clinical context still matters.
The Blood Bank Can Affect More Than the CBC
This case is a good reminder of just how far the consequences of transfusion testing can extend.
An evolving antibody led to incompatible antigen exposure.
That caused hemolysis.
The hemolysis increased bilirubin.
The bilirubin increased the calculated MELD score.
The MELD score changed the patient's apparent mortality risk and transplant urgency.
And the newly identified antibody simultaneously made it harder for the Blood Bank to prepare compatible units for the potential transplant.
That's quite a chain of events from something that initially showed up as:
“nonspecific reactivity.”
The Takeaway
For the Blood Bank, the obvious lesson is to take unexplained serologic reactivity seriously—particularly in heavily transfused or high-risk patients—and to respect historical antibodies even when they later disappear from routine testing.
For the transplant team, the lesson is slightly different:
A MELD score is only as interpretable as the clinical circumstances producing its laboratory values.
A sudden increase in bilirubin in a recently transfused patient does not automatically mean the liver just became dramatically worse.
Look for hemolysis.
Check the hemoglobin.
Look at the LDH.
Check the haptoglobin.
Check the DAT.
Look at the urine.
And call the Blood Bank.
Because sometimes a suddenly catastrophic-looking liver score isn't entirely a liver problem.
Sometimes it's Kidd being Kidd.
0 Comments